VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On February 7, 2019, VBI Vaccines Inc. announced that the independent Data and Safety Monitoring Board (DSMB) completed its third and final safety assessment of Part A of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent glioblastoma (GBM) patients. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press Release dated February 7, 2019|
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients – Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modification – Enrollment is complete in the high-dose study arm of Part A – Expanded immunologic data and 6-month survival data from all three dose cohorts in Part A expected in the first half of 2019 CAMBRIDGE,…
To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).